The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with significant layoffs and leadership upheaval this year.
|
Dublin-based Aerska launched on Wednesday with $21 million in seed funding and a technology designed to shuttle RNA interference medicines past the blood-brain barrier.
|
Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial head Luke Miels on Jan. 1.
|
Explore why chromatography is a critical tool in pharma development and learn how to employ it effectively.
|
Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to standard therapies for Von Willebrand disease.
|
A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.
|
Recommended For You
Improve your recommendations: click here to update your profile.
Deep Dive
Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers.
|
|
Since 2022, Chinese companies account for 31% of the total global drug market. Learn how Western pharma companies can collaborate with China’s booming bioscience sector in this playbook.
|
|
From Our Library
Trendline
Supported by 10x Genomics
|
Trendline
Supported by Catalent
|
View all resources
Best of What We're Reading
| 
